Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Doesn’t Need Conditional Approval Pathway, Cavazzoni Tells House Committee

Jul 30 2021

• By Derrick Gingery

CDER Director Patrizia Cavazzoni answers questions virtually on drug development in neurodegenerative diseases during a House Energy and Commerce Health Subcommittee hearing. • Source: screenshot

Related Content

Aduhelm Invades Senate Committee’s COVID-19 Hearing

Jul 21 2021

Accelerated Approvals Could Have Expiration Dates, Annual Reviews To Promote Confirmatory Trials, ICER Suggests

Apr 29 2021

Alzheimer’s Can Follow HIV And Become Chronic Condition If Science Advances, Woodcock Argues

Jun 11 2021

Accelerated Approvals Could Be Improved By Focusing On Benefit/Risk, Making Withdrawal Easier

Feb 10 2021

Medicare Coverage Analysis Of Alzheimer’s Drugs Begins With Focus On Outcomes, Patient Eligibility

Jul 14 2021

Woodcock Requests Independent Review Of Biogen-FDA Aduhelm Interaction … Not Approval Decision

Jul 10 2021

Finance Watch: $135m In Venture Capital Will Fund Amylyx’s Late-Stage ALS Drug

Jul 22 2021

Related Companies

Amylyx Pharmaceuticals, Inc.

Biogen, Inc.

Eisai Co., Ltd.

Additional Topics

United States Politics Legislation Review Pathway Regulation Neurology BioPharmaceutical

More from Legislation

More from Pink Sheet

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.